<p><em>這家醫療數據和工具提供商有望突破盈虧平衡點，得益於人工智能的普及，但持續盈利的前景仍不確定</em></p>
<p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1024" height="760" original-src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg"/></p>
<p><em><strong>圖片來源：Bamboo Works</strong></em></p>
<h4><strong>關鍵要點：</strong></h4>
<ul>
<li>公司表示預計截至 3 月底的財年將實現淨利潤約為 600 萬至 800 萬美元</li>
<li>醫渡科技的人工智能工具正在被納入醫療工作流程，一些客户醫院的使用頻率接近每天 1000 次</li>
</ul>
<p>多年來，醫療人工智能引發了大量的興奮，但一直難以證明其盈利能力。這種情況可能正在發生變化，因為一家中國醫療科技提供商準備迎來盈利里程碑。</p>
<p><strong>醫渡科技有限公司</strong>（2158.HK）<strong>宣佈</strong> 於 4 月 20 日預計將在其 11 年曆史中首次實現年度盈利，這可能標誌着更廣泛的人工智能驅動醫療行業的轉折點。</p>
<p>這家為醫療行業提供大數據和技術解決方案的供應商預計截至 3 月底的財年將實現淨利潤在 4100 萬至 5600 萬元人民幣（600 萬至 820 萬美元）之間，較去年約 1.18 億元的虧損有所回升。</p>
<p>在解釋扭轉局面時，公司提到新訂單激增，因為它將人工智能整合到其產品中，從而推動了更高的毛利率，以及更好的運營效率和規模經濟。</p>
<p>從醫渡科技的半年財報中可以清楚地看出，該公司正朝着盈虧平衡的方向發展。截止 9 月底的六個月收入增長了 8.7%，達到 3.58 億元，扭轉了去年同期的收縮。毛利率從 35.6% 上升至 37.4%。運營虧損縮小了 71%，降至 1571 萬元，淨虧損縮小了 72%，降至 1576 萬元。</p>
<p>這些中期結果顯示，增長越來越多地由醫院的應用解決方案和支付系統驅動，而不是製藥服務。</p>
<p>公司大數據平台和解決方案的半年收入同比增長 14.6%，而健康管理部門的收入躍升 30.3%。相比之下，針對製藥公司的生命科學解決方案下降了 4.4%。在收入構成方面，大數據平台業務仍然是收入的最大貢獻者。</p>
<p>隨着人工智能的勢頭從大型模型轉向實際部署，投資者越來越關注該技術是否能夠嵌入工作流程以產生回報。在醫療保健領域，這意味着將人工智能整合到臨牀護理、研究或支付系統中。</p>
<p>迄今為止，只有少數中國人工智能醫療公司跨越了盈利門檻。例如，<strong>科大訊飛醫療</strong>（2506.HK）專注於初級護理和語音交互場景。它通過標準化工具迅速擴展，但在 2025 年仍報告虧損 6479 萬元。<strong>Airdoc 科技</strong>（2251.HK）專注於單點應用，如視網膜圖像識別，商業模式相對清晰但有限，去年虧損 2497 萬元。</p>
<p>醫渡科技採取了不同的路徑。在早期階段，公司開發了醫療平台和特定疾病數據庫，建立了大量結構化數據和廣泛的醫院客户基礎。最近，它已從單純提供信息轉變為通過臨牀助手和基於證據的人工智能代理參與醫療決策。</p>
<p>根據半年財報中的使用數據，這些工具似乎正在逐漸融入臨牀工作流程，一些醫院的訪問頻率接近每天 1000 次。這種高頻率的使用可能是從人工智能驅動的醫療業務中產生穩定回報的關鍵。</p>
<p>與此同時，公司在服務超過 1 萬家醫療機構和與 100 多家頂級醫院合作方面展示了可擴展性。然而，廣泛採用與經濟回報之間的相關性尚未明確建立。</p>
<h4><strong>前景不確定</strong></h4>
<p>收入增長仍處於個位數，沒有明顯加速的跡象。根據全年初步數據，很難判斷利潤的可持續性。此外，醫療人工智能的採用高度依賴於醫院採購週期和政府支持政策，影響擴展的速度和範圍。</p>
<p>公司仍可能處於過渡階段，其商業模式正在形成但尚未得到驗證。醫渡科技的盈利突破錶明，人工智能醫療在特定場景中可以實現貨幣化，但可能無法在整個行業中持續或複製。</p>
<p>儘管如此，利潤預測推動了公司股價的上漲。在公告後，股價上漲 3.8%，收於 6.3 港元，年初至今漲幅為 18.4%。醫渡科技的市銷率約為 7.5 倍，基本與科大訊飛醫療的約 8 倍和 Airdoc 科技的約 6 倍相當。這表明投資者仍然基於收入規模和增長潛力而非盈利能力來評估其價值。</p>
<p>如果醫渡科技在接下來的幾個季度內能夠保持盈利並加速收入增長，股價可能還有上漲空間。但如果利潤下滑，估值可能已經達到頂峯。</p>
<p><em>要訂閲 Bamboo Works 每週的免費通訊，請點擊</em> 這裏</p>
<p><strong><em>Benzinga 免責聲明：本文來自未付的外部貢獻者。它不代表 Benzinga 的報道，並且未經過內容或準確性的編輯。</em></strong></p>

醫渡科技

<p>醫渡科技預計將在截至三月的財年中實現首個年度盈利，預計淨利潤為 600 萬至 800 萬美元，這標誌着醫療保健領域人工智能的潛在轉折點。該公司在醫療工作流程中看到其人工智能工具的採用率增加，一些醫院每天使用這些工具近 1000 次。儘管如此，由於收入增長緩慢和對醫院採購週期的依賴，持續盈利的前景仍然不確定。在公告發布後，醫渡科技的股價上漲了 3.8%</p>

<p><em>The provider of healthcare data and tools is poised to pass the breakeven point, helped by rising AI uptake, but the outlook for sustained profits remains uncertain</em></p>
<div class="lb-trans"><p><em>這家醫療數據和工具提供商有望突破盈虧平衡點，得益於人工智能的普及，但持續盈利的前景仍不確定</em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg" alt="" original-src="https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg"/></p>
<p><em><strong>image credit: Bamboo Works</strong></em></p>
<div class="lb-trans"><p><em><strong>圖片來源：Bamboo Works</strong></em></p>
</div><h4><strong>Key Takeaways:</strong></h4>
<div class="lb-trans"><h4><strong>關鍵要點：</strong></h4>
</div><ul>
<li>The company says it expects to post a net profit ranging from around $6 million to $8 million for its financial year to the end of March</li>
<li>Yidu Tech's AI tools are being adopted into medical workflows, with some client hospitals reported to use them nearly 1,000 times a day</li>
</ul>
<div class="lb-trans"><ul>
<li>公司表示預計截至 3 月底的財年將實現淨利潤約為 600 萬至 800 萬美元</li>
<li>醫渡科技的人工智能工具正在被納入醫療工作流程，一些客户醫院的使用頻率接近每天 1000 次</li>
</ul>
</div><p>For years, medical AI has generated plenty of excitement but has struggled to show it can make money. That situation may be starting to change, as one Chinese provider of healthcare technology prepares to mark an earnings milestone.</p>
<div class="lb-trans"><p>多年來，醫療人工智能引發了大量的興奮，但一直難以證明其盈利能力。這種情況可能正在發生變化，因為一家中國醫療科技提供商準備迎來盈利里程碑。</p>
</div><p><strong>Yidu Tech Inc.</strong> (2158.HK) <strong>announced</strong> on April 20 it expects to post the first annual profit in its 11-year history, potentially marking an inflection point for the broader AI-powered healthcare sector.</p>
<div class="lb-trans"><p><strong>醫渡科技有限公司</strong>（2158.HK）<strong>宣佈</strong> 於 4 月 20 日預計將在其 11 年曆史中首次實現年度盈利，這可能標誌着更廣泛的人工智能驅動醫療行業的轉折點。</p>
</div><p>The supplier of big data and tech solutions for the medical sector projected a net profit of between 41 million yuan and 56 million yuan ($6 million and $8.2 million) for its financial year to the end of March, rebounding from a loss of around 118 million yuan in the previous year.</p>
<div class="lb-trans"><p>這家為醫療行業提供大數據和技術解決方案的供應商預計截至 3 月底的財年將實現淨利潤在 4100 萬至 5600 萬元人民幣（600 萬至 820 萬美元）之間，較去年約 1.18 億元的虧損有所回升。</p>
</div><p>In explaining the turnaround, the company cited a surge in new orders as it integrates AI into its products, driving higher gross margins, as well as better operating efficiency and economies of scale.</p>
<div class="lb-trans"><p>在解釋扭轉局面時，公司提到新訂單激增，因為它將人工智能整合到其產品中，從而推動了更高的毛利率，以及更好的運營效率和規模經濟。</p>
</div><p>It was clear from Yidu Tech's half-year earnings that the firm was heading towards breakeven. Revenues for the six months to end-September rose 8.7% to 358 million yuan, reversing a contraction in the year-earlier period. Gross margin rose to 37.4%.  from 35.6% while operating losses narrowed by 71% to 15.71 million yuan and net losses shrank 72% to 15.76 million yuan.</p>
<div class="lb-trans"><p>從醫渡科技的半年財報中可以清楚地看出，該公司正朝着盈虧平衡的方向發展。截止 9 月底的六個月收入增長了 8.7%，達到 3.58 億元，扭轉了去年同期的收縮。毛利率從 35.6% 上升至 37.4%。運營虧損縮小了 71%，降至 1571 萬元，淨虧損縮小了 72%，降至 1576 萬元。</p>
</div><p>Those interim results showed that growth was increasingly being driven by application-based solutions for hospitals and payment systems, rather than pharmaceutical services.</p>
<div class="lb-trans"><p>這些中期結果顯示，增長越來越多地由醫院的應用解決方案和支付系統驅動，而不是製藥服務。</p>
</div><p>Half-year revenue from the company's big data platform and solutions grew 14.6% year on year, while income from the health management segment jumped 30.3%. In contrast, life sciences solutions for pharmaceutical companies slipped 4.4%. In terms of the revenue mix, the big data platform business remains the largest contributor to the top line.</p>
<div class="lb-trans"><p>公司大數據平台和解決方案的半年收入同比增長 14.6%，而健康管理部門的收入躍升 30.3%。相比之下，針對製藥公司的生命科學解決方案下降了 4.4%。在收入構成方面，大數據平台業務仍然是收入的最大貢獻者。</p>
</div><p>As the AI momentum shifts from large models to real-world deployment, investors are increasingly focused on whether the technology can be embedded into workflows to generate returns. In healthcare, that would mean integrating artificial intelligence into clinical care, research or payment systems.</p>
<div class="lb-trans"><p>隨着人工智能的勢頭從大型模型轉向實際部署，投資者越來越關注該技術是否能夠嵌入工作流程以產生回報。在醫療保健領域，這意味着將人工智能整合到臨牀護理、研究或支付系統中。</p>
</div><p>Few Chinese AI healthcare companies have so far crossed the profit threshold. For example, <strong>iFlytek Healthcare</strong> (2506.HK) focuses on primary care and voice interaction scenarios. It has expanded rapidly through standardized tools yet still reported a loss of 64.79 million yuan in 2025. <strong>Airdoc Technology</strong> (2251.HK) concentrates on single-point applications such as retinal image recognition with a relatively clear but limited business model, leaving it with a loss of 24.97 million yuan last year.</p>
<div class="lb-trans"><p>迄今為止，只有少數中國人工智能醫療公司跨越了盈利門檻。例如，<strong>科大訊飛醫療</strong>（2506.HK）專注於初級護理和語音交互場景。它通過標準化工具迅速擴展，但在 2025 年仍報告虧損 6479 萬元。<strong>Airdoc 科技</strong>（2251.HK）專注於單點應用，如視網膜圖像識別，商業模式相對清晰但有限，去年虧損 2497 萬元。</p>
</div><p>Yidu Tech has taken a different path. In its early stages, the company developed medical platforms and disease-specific databases, building a large pool of structured data and a wide base of hospital clients. More recently it has shifted from simply providing information to participating in healthcare decisions through products such as a clinical Copilot and an evidence-based AI agent.</p>
<div class="lb-trans"><p>醫渡科技採取了不同的路徑。在早期階段，公司開發了醫療平台和特定疾病數據庫，建立了大量結構化數據和廣泛的醫院客户基礎。最近，它已從單純提供信息轉變為通過臨牀助手和基於證據的人工智能代理參與醫療決策。</p>
</div><p>These tools appear to be finding their way into clinical workflows, according to usage data contained in the half-year earnings report, with some hospitals reported to be accessing them nearly 1,000 times a day. Such high-frequency uptake could be the key to generating stable returns from the business of AI-powered healthcare.</p>
<div class="lb-trans"><p>根據半年財報中的使用數據，這些工具似乎正在逐漸融入臨牀工作流程，一些醫院的訪問頻率接近每天 1000 次。這種高頻率的使用可能是從人工智能驅動的醫療業務中產生穩定回報的關鍵。</p>
</div><p>Meanwhile, the company has demonstrated scalability in serving more than 10,000 medical institutions and partnering with over 100 top-tier hospitals. However, a correlation between wide take-up and monetary returns has yet to be clearly established.</p>
<div class="lb-trans"><p>與此同時，公司在服務超過 1 萬家醫療機構和與 100 多家頂級醫院合作方面展示了可擴展性。然而，廣泛採用與經濟回報之間的相關性尚未明確建立。</p>
</div><h4><strong>Uncertain outlook</strong></h4>
<div class="lb-trans"><h4><strong>前景不確定</strong></h4>
</div><p>Revenue growth remains in the single digits, with no clear sign of acceleration. Based on the outline figures for full year, it is hard to determine how sustainable the profits will be. Moreover, the adoption of healthcare AI is highly dependent on hospital procurement cycles and supportive government policies, affecting the pace and scope of expansion.</p>
<div class="lb-trans"><p>收入增長仍處於個位數，沒有明顯加速的跡象。根據全年初步數據，很難判斷利潤的可持續性。此外，醫療人工智能的採用高度依賴於醫院採購週期和政府支持政策，影響擴展的速度和範圍。</p>
</div><p>The company could still be in a transitional stage in which its business model is taking shape but remains unproven. Yidu Tech's earnings breakthrough shows that AI healthcare can be monetized in specific scenarios, but it may not be sustainable or replicated across the whole sector.</p>
<div class="lb-trans"><p>公司仍可能處於過渡階段，其商業模式正在形成但尚未得到驗證。醫渡科技的盈利突破錶明，人工智能醫療在特定場景中可以實現貨幣化，但可能無法在整個行業中持續或複製。</p>
</div><p>Still, the profit projection lifted the company's shares. After the announcement, the stock rose 3.8% to close at HK$6.3, for a year-to-date gain of 18.4%. Yidu Tech is trading at a price-to-sales ratio of about 7.5 times, broadly in line with iFlytek Healthcare at around 8 times and Airdoc Technology at about 6 times. This suggests investors are still basing their valuation on revenue scale and growth potential, rather than profitability.</p>
<div class="lb-trans"><p>儘管如此，利潤預測推動了公司股價的上漲。在公告後，股價上漲 3.8%，收於 6.3 港元，年初至今漲幅為 18.4%。醫渡科技的市銷率約為 7.5 倍，基本與科大訊飛醫療的約 8 倍和 Airdoc 科技的約 6 倍相當。這表明投資者仍然基於收入規模和增長潛力而非盈利能力來評估其價值。</p>
</div><p>If Yidu Tech can stay in the black over the next few quarters and accelerate its revenue growth, the stock may have room to rise. But if profits falter, the valuation may have already peaked out.</p>
<div class="lb-trans"><p>如果醫渡科技在接下來的幾個季度內能夠保持盈利並加速收入增長，股價可能還有上漲空間。但如果利潤下滑，估值可能已經達到頂峯。</p>
</div><p><em>To subscribe to Bamboo Works weekly free newsletter, click</em> here</p>
<div class="lb-trans"><p><em>要訂閲 Bamboo Works 每週的免費通訊，請點擊</em> 這裏</p>
</div><p><strong><em>Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.</em></strong></p>
<div class="lb-trans"><p><strong><em>Benzinga 免責聲明：本文來自未付的外部貢獻者。它不代表 Benzinga 的報道，並且未經過內容或準確性的編輯。</em></strong></p>
</div>

Yidu Tech Swings To Profit Signaling An Inflection Point For AI Healthcare

- Yidu Tech 預計實現首個年度淨利潤，範圍為 600 萬至 800 萬美元。  
- 醫療 AI 被快速應用於臨牀工作流程，部分醫院每日使用近 1,000 次。  
- 盈利前景仍存不確定性， revenue 增長乏力，受醫院採購和政策影響。

醫渡科技實現盈利，標誌着人工智能醫療保健領域的一個拐點